Tazarotene
- Generic Name
- Tazarotene
- Brand Names
- Arazlo, Duobrii, Fabior, Tazorac
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21NO2S
- CAS Number
- 118292-40-3
- Unique Ingredient Identifier
- 81BDR9Y8PS
- Background
Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).
- Indication
Used to treat psoriasis, acne and sun damaged skin (photodamage).
- Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis), Benign facial lentigines, Facial fine wrinkling, Facial hyperpigmentation, Facial hypopigmentation, Mild Acne vulgaris, Moderate Acne vulgaris
New Guidelines and Therapies Reshape Acne Treatment Approach in 2025
• The American Academy of Dermatology's 2024 updated acne guidelines recommend limiting systemic antibiotic use and emphasize treating all four pillars of acne pathogenesis simultaneously.
• Several new FDA-approved acne medications since 2019 have expanded treatment options, including Winlevi (clascoterone), the only topical therapy effective for excessive sebum production.
• Dermatology experts now recommend simpler treatment regimens with fewer products that address multiple pathogenic factors, with a growing focus on early intervention to prevent scarring.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath